[Problem of cardiogenic shock therapy].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000700:Analgesics; D000804:Angiotensin II / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001243:Assisted Circulation; D001544:Benperidol / Q000627:therapeutic use; D002301:Cardiac Glycosides / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D009203:Myocardial Infarction / Q000150:complications; D009458:Neuroleptanalgesia; D009638:Norepinephrine / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D012770:Shock, Cardiogenic / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*
D000305:Adrenal Cortex Hormones; D000700:Analgesics; D000925:Anticoagulants; D002301:Cardiac Glycosides; D003911:Dextrans; D005343:Fibrinolytic Agents; D010643:Phenoxybenzamine; D000804:Angiotensin II; D001544:Benperidol; D006854:Hydrocortisone; D009638:Norepinephrine
Problemy terapii kardiogennogo shoka.